• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • Highlights of India’s first Biotech startup Expo
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid
  • Moderna and Pfizer: Lawsuits and Charitable Giving
  • European Commission Approves Two GM Crops for Food and Feed
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

    January 23, 2022

    Interview – Dr Heera Lal: How an IAS officer using Biotech approaches to transform Indian villages into “Organic Villages”

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»SARS- CoV2 & COVID-19 Updates»Editorial: COVAXIN- How the only Indian indigenous COVID vaccine of International repute is lagging in world’s race

Editorial: COVAXIN- How the only Indian indigenous COVID vaccine of International repute is lagging in world’s race

0
By Biotech Express on May 23, 2021 SARS- CoV2 & COVID-19 Updates

Kamal Pratap Singh

Pfizer eyes $26B in COVID-19 vaccine sales for the year 2021, with $3.5B (360 crore Rs) already in the bag. Moderna has predicted output of up to 1 billion doses this year. Adar Poonawalla on May 1 announced that the Serum Institute would be able to raise its monthly output to 100 million (10 crore) doses by July. India approved Russian made Sputnik V also, and is also planning to approve vaccines made by Pfizer, Moderna, Johnson & Johnson and others.

Pfizer is making 300 crore doses (3 billion) whereas Indian vaccine manufacturer consortium of Bharat Biotech will make only 90 crore doses till the end of 2021.

The finance ministry approved ₹3,000 crore for Pune-based SII which is manufacturing the AstraZeneca’s COVID-19 vaccine Covishield but granted ₹1567.50 crores to Hyderabad-based Bharat Biotech for boosting the production of indigenous Covaxin.

India recently set the milestone of vaccinating more than 180 million (18 crore) people.

Centre’s statement that India will produce over 216 crore vaccine doses between August and December represents an ambitious scaling up of manufacturing capacity of India. Current workhorses Covishield and Covaxin will yield 75 crore and 55 crore doses respectively (around 50%), while others including Sputnik V and vaccines under trial from Novavax, Zydus Cadila, Biological E and Bharat Biotech’s nasal vaccine will contribute the rest.

COVAXIN®, India’s only indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) high containment facility. The vaccine is developed using Whole-Virion Inactivated Vero Cell derived platform technology. Inactivated vaccines do not replicate and are therefore unlikely to revert and cause pathological effects. They contain dead virus, incapable of infecting people but still able to instruct the immune system to mount a defensive reaction against an infection.

Conventionally, inactivated vaccines have been around for decades and are found safest. Numerous vaccines for diseases such as Seasonal Influenza, Polio, Pertussis, Rabies, and Japanese Encephalitis use the same technology to develop inactivated vaccines with a safe track record. It is thus the well-established, and time-tested platform in the world of vaccine technology.

“Manufacturing scale-up has been carried out in a stepwise manner across multiple facilities in Hyderabad and Bengaluru but still it is limited to 700 million (70 crore) doses…,” said the company on April 20th, 2021, which had in January pegged the capacity at 200 million doses a year. Bharat Biotech CMD Krishna Ella at an event in April 2021 said that the company will produce 30 million (3 crore) doses of Covaxin next month (May) against around 20 million (2 crore) doses this month (April) and 15 million in the last month (March). He said that the company expects to reach a production capacity of up to 700 million doses per annum by July-August 2022.

The Union health ministry said the government has paid an advance of ₹1,699.50 crore, after deducting tax at source, to Serum Institute for 110 million (11 crore) doses of Covishield, as well as ₹772.50 crore to Bharat Biotech for 50 million (5 crore) doses of Covaxin. Both payments were made on 28 April.

On May 10, union aviation minister Hardeep Singh Puri has said advance orders for May, June and July have been placed. Puri said the central government has placed advance orders with SII, buying 5.6 crore vaccines worth Rs 1,176 crore through PM Care fund. To Bharat Biotech, he said the Centre has placed orders for 1 crore vaccines worth Rs 216.83 crore through PM Cares; and 5 crore doses on April 22 and 2 crore on May 10 by the health ministry.

Cumulatively, Indian vaccine manufacturers, including SII, Bharat Biotech, Panacea Biotech, Sanofi’s Shanta Biotech, Biological E, Hester Biosciences and Zydus Cadila, have an installed capacity to manufacture 8.2 billion doses of different vaccines per year out of which companies have already planned to give 5.4 billion covid vaccine doses in a year.

If required, total vaccine production capacity can be tweaked to manufacture COVID-19 vaccines. Besides vaccinating every citizen of the country, it can be used to supply vaccines to other countries of the world.

Points to consider while deciding manufacturing and expansion capacities of Bharat Biotech
– Only COVAXIN is indigenous and safe vaccine which has been developed in India
– Bharat Biotech has world class manufacturing expertise approved by USFDA, KFDA and WHO
– Demonstrating capabilities of world’s first: Eco-friendly recombinant Hepatitis-B vaccine (free of cesium chloride and Thiomersal), Rotavirus vaccine from a naturally attenuated strain and Typhoid Conjugate vaccine.
– Among the first in India to develop vaccines for viral diseases like Chikungunya and Zika.
– Bharat Biotech produces largest number of different kind of vaccines.
– Pfizer, the largest contender of COVID-19 vaccine has very stringent storage conditions which can result in unnecessary loss of doses.
– It is effective against emerging mutants.

Recently, the Centre has provided financial assistance in the form of grant of Rs 220 crore to vaccine manufacturers to boost the production of Bharat Biotech’s COVID-19 vaccine Covaxin, and its production is expected to reach more than 10 crore doses per month by September this year (Table).

Conclusion:
Bharat Biotech is perfect candidate for Atma Nirbhar Bharat vaccine production which has ramp-up production to 500 million (50 crore) doses a year. US’s Pfizer has expected to produce 3 billion vaccines but it can be beaten up if 10 such facilities of Bharat Biotech being built up by govt through a more robust investment in the future indigenous vaccine industry of India. As we calculated it will bring more than 3 billion doses which otherwise a target of Pfizer and at the same time we can vaccinate the whole world with a safe and cost effective COVAXIN through FDA, EU, WHO, CEPI, GAVI, COVAX and other alliances.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Researchers who jumped into the field from distant disciplines published lower impact work, study finds

Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid

No Vaccine Mandates after supreme court order, next compensation to AEFI survivors from COVID Vaccine makers possible?

Leave A Reply Cancel Reply

Current Issue – May 2022

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • Highlights of India’s first Biotech startup Expo June 13, 2022
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity June 6, 2022
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds May 30, 2022
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft May 26, 2022
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak May 25, 2022
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid May 25, 2022
  • Moderna and Pfizer: Lawsuits and Charitable Giving May 25, 2022
  • European Commission Approves Two GM Crops for Food and Feed May 25, 2022
  • Ayush Ministry, DBT sign MoU for cooperation on evidence-based biotech interventions in Ayush sector May 24, 2022
  • CCI, India merger approved absorption of Covidshield Technologies into Biocon Biologics May 20, 2022
  • No Vaccine Mandates after supreme court order, next compensation to AEFI survivors from COVID Vaccine makers possible? May 19, 2022
  • Industry lobbying on WHO overshadowing public health policy, researchers suggest May 18, 2022
  • Letter: Public Health Bill to be presented in the Monsoon session 2022 is Illegal, Unconstitutional and Arbitrary: Dr Maya Valecha May 15, 2022
  • Paid publishing in science has killed peer review system, says CSIR’s ex-chief Shekhar Mande May 15, 2022
  • Bill Gates tests positive for COVID-19 even after many booster doses, mocked on twitter May 10, 2022
  • Another Ivermectin COVID-19 paper retracted May 8, 2022
  • COVID-19 spike protein paper retracted May 7, 2022
  • Killer Music? Can sound make a clot in a boy who died while dancing or it is related to COVID vaccination May 7, 2022
  • Clotting Risks Cause FDA to Restrict Use of J&J COVID Vaccine May 6, 2022
  • Department of Pharmaceuticals releases “Common Guidelines on Pharmaceutical Innovation and Entrepreneurship” for academic institutions May 6, 2022
  • No medical care for 45% of recorded deaths in 2020, highest ever in India: New data May 6, 2022
  • Indian opposition seeks higher compensation for COVID deaths after damning WHO report May 6, 2022
  • Redcliffe Lifetech raises $61 million in Series B funding May 6, 2022
  • Engineers Create an Enzyme That Breaks Down Plastic Waste in Hours, Not Decades May 5, 2022
  • Eris Lifesciences acquires 100% stake in Oaknet Healthcare for Rs 650 cr May 5, 2022
  • The Union Government has Lied to the Supreme Court in COVID Vaccines Case? May 5, 2022
  • COVID-19- vitamin D paper from India retracted by Springer Nature journal May 4, 2022
  • IISc develops 3D printed gloves for rehabilitating stroke patients May 4, 2022
  • A new wearable technology — for plants May 4, 2022
  • Sanofi India names Rodolfo Hrosz managing director effective June 1 May 4, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.